ACE2 and COVID-19: The binding of anti-ACE2 antibodies to ACE2 in normal cells could have the potential to mediate profound pathophysiological effects long after the original antigen itself has disappeared, particularly in the long term COVID-19 patients (e.g., possibly inducing myocarditis or neurological illnesses; Figure 7).